TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| The ABCs of Missing Vitamins Americans and their kids have been consuming growing quantities of dietary supplements in recent years. But some pediatricians say the growth in supplement sales suggests children may be popping too many pills. online.wsj.com |
The Problem With Somaxon's Silenor Douglas Krohn submits:The next time you buy an over-the-counter sleep medication, look carefully at the active ingredient. Turn the bottle over in your hands a couple times, read your way through the fine print, and then, after you’ve struggled to pronounce the name of what seems to be such a foreign molecule – diphenhydramine, which is usually the stuff of over-the-counter sweet dreams – stroll on over to the allergy medication aisle, pick up a bottle of Benadryl, and do the same. If you are overcome by a feeling of déjà vu while perusing the label for a hay fever remedy, don’t be shaken: the active ingredient in Benadryl, long used for sniffles and itchy eyes, is also diphenhydramine. Unisom, the once popular OTC medication for those who cannot settle down at night, is yet another incarnation of diphenhydramine. And so is Tylenol PM, at least in part: it is acetaminophen (the active ingredient in Tylenol), but mixed in with – you guessed it – diphenhydramine.Complete Story » seekingalpha.com |
Medco Profit Up 14% Medco's second-quarter profit rose 14%, as revenue increased more than expected. online.wsj.com |
LabCorp Enters into Definitive Agreement to Acquire Genzyme Genetics [Business Wire] - BURLINGTON, N.C.----Laboratory Corporation of America® Holdings , today announced that it has entered into a definitive agreement under which LabCorp will acquire Genzyme Genetics, a business unit of Genzyme Corp. , in an all cash transaction valued at $925 million. us.rd.yahoo.com |
Why Next-Gen Biofuels Look Attractive for Biotech Investors The Burrill Report submits: By John Hamer It’s interesting that biotech publications focused on healthcare have reported the news of the Amyris (AMRS) IPO, a next-generation biofuel company. Biotech investors will probably look seriously at this area. Much of the underlying technology, such as genomics and synthetic biology, is shared with traditional biotechs. The first two companies out of the chute, Amyris and Codexis (CDXS), also have healthcare-related projects. What do next-generation biofuel companies offer the biotech investor? Complete Story » seekingalpha.com |